# BPC-157 TB-500 References: The Cited Wolverine Blend Literature and FDA Record

> BPC-157 TB-500 references — the full citation list for the Wolverine blend digest: PubMed-indexed component studies, the 2025-2026 systematic reviews, and the FDA 503A and PCAC regulatory sources, with DOIs and URLs.

Every quantitative claim on this site resolves to one of the entries below — the peer-reviewed component literature, the 2025-2026 systematic reviews, and the FDA regulatory record.

## How this register is organized

This is the citation register for the Wolverine blend digest. Entries 1-6 are the peer-reviewed single-component literature for BPC-157 and TB-500 / Thymosin Beta-4. Entries 7-9 are the 2025-2026 systematic and narrative reviews that bound the evidence and the safety picture. Entries 10-12 are the FDA regulatory sources behind the [Wolverine legal status and FDA 503A compounding access](/legal-status) page.

The blend has no combination literature of its own — that absence is itself the central finding [7]. Each numbered marker across the [combination rationale and synergy claim](/research), the [BPC-157 and TB-500 benefits for tendon and tissue recovery](/recovery-research) page, the dosage record, and the FAQ points back to one of these entries. The [full reference list with PMIDs and DOIs](/references) is below.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. https://pubmed.ncbi.nlm.nih.gov/22962027/
[6] Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. https://pubmed.ncbi.nlm.nih.gov/23084823/
[7] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical and 1 human; "shows promise" only from level IV-V evidence; no clinical safety data; no mention of TB-500 or combination use.) https://pubmed.ncbi.nlm.nih.gov/40756949/
[8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Animal-model promise but scarce human safety data and potential for serious harm; unapproved peptides including BPC-157 and TB-500 / thymosin beta-4 operate largely outside regulatory oversight.) https://pubmed.ncbi.nlm.nih.gov/41966639/
[9] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human data limited to three small pilot studies; considered investigational given regulatory controversy and non-regulated availability.) https://pubmed.ncbi.nlm.nih.gov/40789979/
[10] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; effective with the September 29, 2023 list update; cited safety rationale includes potential immunogenicity for certain routes and impurity/characterization complexity. Verified 2026-05-29.) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[11] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B compounding framework and bulks-list/nomination process; the prescriber-evaluation access pathway. Verified 2026-05-29.) https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[12] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Published agenda lists BPC-157 and TB-500 among bulk drug substances being considered for inclusion on the 503A bulks list; a scheduled discussion of substances under evaluation, not a decision or outcome. Verified 2026-05-29.) https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

The Wolverine blend kept as a kiln-fired formulary entry — BPC-157 and TB-500 set down as two annotated specimens, their measured animal-model findings inked and their unproven join left in the warm margin, with the FDA 503A and WADA record pinned to the page and nothing here prescribed or sold.